|
Links to NCI Materials
The Breast Cancer Prevention Trial (BCPT) was designed to see whether taking the drug tamoxifen (Nolvadex®) can prevent breast cancer in women who are at an increased risk of developing the disease. The BCPT was also looking at whether taking tamoxifen decreases the number of heart attacks and reduces the number of bone fractures in these women (see the protocol summary).
The study began recruiting participants in April 1992 and closed enrollment in September 1997; 13,388 women ages 35 and older were enrolled. Researchers with the
National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted the study in more than 300 centers across the United States and Canada. The study (also called the P-1 trial) was funded by the National Cancer Institute (NCI), the United States' primary agency for cancer research.
Final Results from the NSABP Breast Cancer Prevention Trial Reported
(Posted: 11/15/2005) - Researchers from the National Surgical Adjuvant Breast and Bowel Project who conducted the landmark Breast Cancer Prevention Trial, report a seven-year and final update of the trial results. In this final report, reductions in breast cancer incidence among participants taking tamoxifen were found to be very similar compared to those reported in 1998 when initial findings were released.
No Link Between Tamoxifen and Depression
(Posted: 11/09/2001, Reviewed: 11/14/2005) - Treatment with tamoxifen does not increase the risk of depression, according to the November 6, 2001, issue of the Journal of the National Cancer Institute.
Breast Cancer Prevention Studies
(Reviewed: 07/23/2008) - A fact sheet about three clinical trials studying methods of preventing breast cancer. National Cancer Institute Fact Sheet 4.18
|
